# AVLN (Avalyn Pharma Inc.) - SEC EDGAR Financial Statements

> Avalyn Pharma Inc. reported $399.3M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/AVLN
- Markdown: https://convexityos.com/fundamentals/AVLN.md
- SEC CIK: 0001540171
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:27 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001540171&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $327.5M | Total debt: $16.93M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $25.49M | $24.73M | $22.89M | $22.09M | $17.88M | $15.32M |
| Total Operating Expenses | $33.09M | $31.29M | $27.91M | $25.32M | $21.78M | $18.72M |
| **Operating Income** | -$33.09M | -$31.29M | -$27.91M | -$25.32M | -$21.78M | -$18.72M |
| **EBITDA** | -$32.99M | -$31.18M | -$27.85M | -$25.31M | -$21.77M | -$18.71M |
| Interest Income | $3.76M | $2.70M | $1.12M | $1.79M | $1.63M | $1.25M |
| Interest Expense | $277K | $272K | $98K | $1.0K | $0 | $0 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$29.66M | -$28.93M | -$26.87M | -$23.58M | -$20.19M | -$17.50M |
| Basic EPS | -$0.67 | -$0.98 | -$21.83 | -$20.34 | -$17.63 | -$63.24 |
| **Diluted EPS** | -$0.67 | -$0.98 | -$21.83 | -$20.34 | -$17.63 | -$63.24 |
| Basic Shares Outstanding | 44.4M | 29.7M | 1.2M | 1.2M | 1.1M | 276.8K |
| Diluted Shares Outstanding | 44.4M | 29.7M | 1.2M | 1.2M | 1.1M | 276.8K |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $145.4M | $264.2M | $92.31M | $52.31M |
| Short-Term Investments | $182.0M | $88.23M | $30.82M | $86.04M |
| **Cash & Short-Term Investments** | $327.5M | $352.4M | $123.1M | $138.4M |
| **Total Current Assets** | $333.7M | $358.0M | $130.0M | $143.6M |
| Property, Plant & Equipment, Net | $1.17M | $1.21M | $1.26M | $792K |
| Long-Term Investments | $59.14M | $61.10M | -- | $0 |
| Other Non-Current Assets | $3.32M | $3.01M | $3.00M | $3.00M |
| **Total Non-Current Assets** | $65.59M | $67.46M | $5.68M | $5.32M |
| **Total Assets** | $399.3M | $425.4M | $135.7M | $148.9M |
| Accounts Payable | $2.70M | $2.65M | $3.15M | $3.76M |
| **Total Current Liabilities** | $12.96M | $10.81M | $11.79M | $14.09M |
| Long-Term Debt | $14.82M | $14.80M | $14.81M | $0 |
| **Total Non-Current Liabilities** | $16.09M | $16.29M | $15.90M | $1.23M |
| **Total Liabilities** | $29.05M | $27.10M | $27.69M | $15.32M |
| **Total Debt (incl. Leases)** | $16.93M | $17.11M | $16.41M | $1.67M |
| Common Stock | $67K | $67K | $24K | $24K |
| Retained Earnings | -$350.8M | -$321.2M | -$292.2M | -$265.4M |
| Accumulated Other Comp. Income | -$994K | -$95K | $12K | $134K |
| **Total Stockholders' Equity** | $370.2M | $398.3M | -$264.2M | -$238.7M |
| Total Equity | $370.2M | $398.3M | -$264.2M | -$238.7M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$29.66M | -$28.93M | -$26.87M | -$23.58M | -$20.19M | -$17.50M |
| Depreciation & Amortization | $104K | $110K | $63K | $9.0K | $9.0K | $10K |
| Stock-Based Compensation | $3.10M | $2.79M | $1.19M | $725K | $1.13M | $543K |
| Change in Payables | $146K | -$93K | -$1.11M | $2.58M | -$364K | -$1.01M |
| **Operating Cash Flow** | -$26.27M | -$26.08M | -$29.89M | -$17.31M | -$20.70M | -$19.27M |
| Capital Expenditure | -$72K | -$269K | -$318K | -$84K | $0 | -$8.0K |
| **Free Cash Flow** | -$26.34M | -$26.34M | -$30.21M | -$17.39M | -$20.70M | -$19.28M |
| Purchases of Investments | -$106.2M | -$134.8M | $0 | -$42.24M | -$64.19M | -$2.87M |
| **Investing Cash Flow** | -$91.77M | -$118.7M | $55.02M | -$26.32M | -$36.69M | $24.12M |
| Common Stock Issued | -- | -- | $50.00M | -- | -- | -- |
| **Financing Cash Flow** | -$733K | $316.7M | $14.86M | $9.90M | $89.88M | $0 |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 25.76x | 33.12x | 11.03x | -- | -- | -- |
| Quick Ratio | 25.28x | 32.60x | 10.45x | -- | -- | -- |
| Debt to Equity | 0.05x | 0.04x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
